Nirali N. Shah, M.D., M.H.Sc.

Nirali N. Shah, M.D., M.H.Sc.

  • Center for Cancer Research
  • National Cancer Institute
Pediatric Oncology Branch


Dr. Shah is a physician scientist who serves as the Head of the Hematologic Malignancies Section of the Pediatric Oncology Branch. Her research focuses on the development of targeted immunotherapy approaches to treat high-risk blood cancers, such as leukemia and lymphoma, in children, adolescents, and young adults. She is also interested in the prevention and treatment of relapsed disease after allogeneic hematopoietic stem cell transplantation. Her clinical trials focus on exploring and improving chimeric antigen receptor (CAR) T-cell based therapies and other antibody-based therapies to target surface proteins found on leukemia cells to improve outcomes for patients with blood cancers that do not respond to chemotherapy. Her research aims to reduce the toxicities and late effects of these therapies. Dr. Shah also served as the NCI Fellowship Program director for the joint Johns Hopkins Hospital-National Cancer Institute Pediatric Hematology-Oncology Fellowship Program and is an alumnus of the program.

Areas of Expertise

Information for Patients

Learn more about the Leukemia, Lymphoma, Transplant and Cell Therapy Team and clinical trials. 

Clinical Trials


Selected Publications

Characterization of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR T-Cells

Daniel A Lichtenstein, Fiorella Schischlik, Lipei Shao, Seth M Steinberg, Bonnie Yates, Hao-Wei Wang, Yanyu Wang, Jon Inglefield, Alina Dulau Florea, Francesco Ceppi, Leandro C Hermida, Kate Stringaris, Kim Dunham, Philip John Homan, Parthav Jailwala, Justin Mateen Mirazee, Welles Robinson, Karen Chisholm, Constance M Yuan, Maryalice Stetler-Stevenson, Amanda K Ombrello, Jianjian Jin, Terry J Fry, Naomi Taylor, Steven L Highfill, Ping Jin, Rebecca A Gardner, Haneen Shalabi, Eytan Ruppin, David F Stroncek, Nirali N Shah
Blood. 2021.
Full-Text Article
[ Journal Article ]

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL
Nat Med.. 24: 20-28, 2018. [ Journal Article ]

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Nirali N Shah, Daniel W Lee, Bonnie Yates, Constance M Yuan, Haneen Shalabi, Staci Martin, Pamela L Wolters, Seth M Steinberg, Eva H Baker, Cindy P Delbrook, Maryalice Stetler-Stevenson, Terry J Fry, David F Stroncek, Crystal L Mackall
Journal of Clinical Oncology. 39/15: 1650-1659, 2021.
Full-Text Article
[ Journal Article ]

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL

Regina M Myers, Agne Taraseviciute, Seth M Steinberg, Adam J Lamble, Jennifer Sheppard, Bonnie Yates, Alexandra E Kovach, Brent Wood, Michael J Borowitz, Maryalice Stetler-Stevenson, Constance M Yuan, Vinodh Pillai, Toni Foley, Perry Chung, Lee Chen, Daniel W Lee, Colleen Annesley, Amanda DiNofia, Stephan A Grupp, Samuel John, Deepa Bhojwani, Patrick A Brown, Theodore W Laetsch, Lia Gore, Rebecca A Gardner, Susan R Rheingold, Michael A Pulsipher, Nirali N Shah
Journal of Clinical Oncology . 2021.
Full-Text Article
[ Journal Article ]

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

Nirali N Shah, Steven L Highfill, Haneen Shalabi, Bonnie Yates, Jianjian Jin, Pamela L Wolters, Amanda Ombrello, Seth M Steinberg, Staci Martin, Cindy Delbrook, Leah Hoffman, Lauren Little, Anusha Ponduri, Haiying Qin, Haris Qureshi, Alina Dulau-Florea, Dalia Salem, Hao-Wei Wang, Constance Yuan, Maryalice Stetler-Stevenson, Sandhya Panch, Minh Tran, Crystal L Mackall, David F Stroncek, Terry J Fry
Journal of Clinical Oncology. 2020.
Full-Text Article
[ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.


Headshot of Bonnie Yates
Research Nurse
Bonnie Yates, R.N.
Headshot of Toni Foley.
Research Nurse
Toni Foley, R.N.
Headshot of Lauren Little
Research Nurse
Lauren Little, R.N.
Headshot of Chloe Hoang
Postbaccalaureate Fellow
Chloe Hoang
Headshot of Grace
Nurse Practitioner
Headshot of Chris Chien
Christopher D. Chien, Ph.D.


10 Years of CAR T-cells in POB - July 2022
A banner showing an immune cell celebrating the 10 year anniversary of CAR T cells in POB.

On July 13th 2022, the POB celebrated the 10 year anniversary of the first patient infused with CD19 CAR T-cells in POB. Dr. Nirali Shah hosted a Special Symposium which honored patients and families and presented key advancements in immunotherapy research. Several members of the CAR T-cell research field gave their thoughts and reflections. Learn more about POB's CAR research efforts through the CARnation Consortium here.